Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-18 21:59 |
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novem…
|
French | PDF • 121.5 KB | ||
| 2023-12-18 19:12 |
Sanofi : Déclaration des transactions sur actions propres
|
French | PDF • 1.5 MB | ||
| 2023-12-18 19:12 |
Sanofi: Disclosure of trading in own shares
|
English | PDF • 2.4 MB | ||
| 2023-12-15 07:30 |
Communiqué de presse : Mise en ligne du document «Q4 2023 Memorandum for modell…
|
French | PDF • 148.1 KB | ||
| 2023-12-15 07:30 |
Press Release: Availability of the Q4 2023 Memorandum for modelling purposes
|
English | PDF • 137.7 KB | ||
| 2023-12-15 07:00 |
Communiqué de presse : L’EMA a rendu un avis favorable pour le Fexinidazole Win…
|
French | PDF • 205.7 KB | ||
| 2023-12-15 07:00 |
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first ora…
|
English | PDF • 197.0 KB | ||
| 2023-12-11 22:08 |
Press Release: Statement on FTC challenge to proposed license agreement with Ma…
|
English | PDF • 135.5 KB | ||
| 2023-12-11 22:08 |
Communiqué de presse : Déclaration au sujet de la contestation par la FTC du pr…
|
French | PDF • 146.6 KB | ||
| 2023-12-11 01:30 |
CP : Sarclisa® (isatuximab) plus KRd améliore significativement le taux de mala…
|
French | PDF • 237.1 KB | ||
| 2023-12-11 01:30 |
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of m…
|
English | PDF • 226.5 KB | ||
| 2023-12-07 07:35 |
CP : L’essai de phase III consacré au Sarclisa® (isatuximab) a atteint son crit…
|
French | PDF • 233.2 KB | ||
| 2023-12-07 07:35 |
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of pro…
|
English | PDF • 223.7 KB | ||
| 2023-12-07 03:30 |
Communiqué de presse : Sanofi sur la voie du leadership mondial en immunologie …
|
French | PDF • 211.1 KB | ||
| 2023-12-07 03:30 |
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Re…
|
English | PDF • 204.2 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
